

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

WOLF GREENFIELD & SACKS, PC FEDERAL RESERVE PLAZA 600 ATLANTIC AVENUE BOSTON MA 02210-2211	uicl	Y	Yuichi	Yuichi Ot	i Obata		L04	61/7112	2 (JRV/M	ЛХА)	6	680
WOLF GREENFIELD & SACKS, PC FEDERAL RESERVE PLAZA 600 ATLANTIC AVENUE BOSTON, MA, 02210-2211												
FEDERAL RESERVE PLAZA 600 ATLANTIC AVENUE BOSTON, MA, 02210-2211												
600 ATLANTIC AVENUE BOSTON, MA 02210-2211									-	EXAMIN	NER	
BOSTON MA 02210-2211	НС		HOLL	LERAN, ANNE L								
ART UNIT PAPER												
							İ	ART	UNIT		PAPER	NUMBE
1642								1	1642			_
DATE MAILED: 10/22/2002							DATI	E MAIL	ED: 10/2	22/2002		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)								
09/835,992 OBATA, YUICHI										
Office Action Summary Examiner Art Unit										
	Anne Holleran	1642								
The MAILING DATE of this communication app	<u> </u>									
Period for Reply		·								
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailing eamed patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be till within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	mely filed ys will be considered timely. the mailing date of this communication. ED (35 U.S.C. § 133).								
Status	l., l., 2002									
1) Responsive to communication(s) filed on 31 J	 									
<u>, </u>	is action is non-final.									
3) Since this application is in condition for allows closed in accordance with the practice under Disposition of Claims	-									
4)⊠ Claim(s) <u>1-32</u> is/are pending in the application	l .									
4a) Of the above claim(s) <u>1-12 and 18-30</u> is/are										
5) Claim(s) is/are allowed.	5) Claim(s) is/are allowed.									
6) Claim(s) is/are rejected.										
7) Claim(s) is/are objected to.										
8) Claim(s) 13-17, 31 and 32 are subject to restrict	ction and/or election requirement	t.								
Application Papers										
9) The specification is objected to by the Examine	r. ,									
10)☐ The drawing(s) filed on is/are: a)☐ accept	oted or b) objected to by the Exa	aminer.								
Applicant may not request that any objection to the	e drawing(s) be held in abeyance. S	See 37 CFR 1.85(a).								
11) The proposed drawing correction filed on		oved by the Examiner.								
If approved, corrected drawings are required in rep										
12) The oath or declaration is objected to by the Ex	aminer.									
Priority under 35 U.S.C. §§ 119 and 120										
13) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a	a)-(d) or (f).								
a) ☐ All b) ☐ Some * c) ☐ None of:										
1. Certified copies of the priority documents	s have been received.									
2. Certified copies of the priority documents	s have been received in Applicat	ion No								
3. Copies of the certified copies of the prior application from the International Bu * See the attached detailed Office action for a list	reau (PCT Rule 17.2(a)).	_								
14) Acknowledgment is made of a claim for domestic	c priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) The translation of the foreign language pro	• •									
Attachment(s)										
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)								

Application/Control Number: 09/835,992 Page 2

Art Unit: 1642

DETAILED ACTION

1. The election of group III in the reply to the restriction requirement is acknowledged.

Upon reconsideration, a further restriction requirement is required.

2. Prior to setting forth the restriction requirement, it is noted that the claims recite improper Markush Groups. M.P.E.P. 803.02 states that: Since the decisions in *In re Weber*, 580 F.2d 455, 198 USPQ 328 (CCPA 1978); and *In re Haas*, 580 F.2d 461,198 USPQ 334 (CCPA 1978), it is improper for the Office to refuse to examine that which applicants regard as their invention, *unless the subject matter in a claim lacks unity of invention* [emphasis added], *In re Harnish*, 631 F.2d 716, 206 USPQ 300 (CCPA 1980); and *Ex parte Hozumi*, 3 USPQ2d 1059 (Bd. Pat. App. & Int. 1984). Broadly, unity of invention exists where compounds included within a Markush group (1) share a common utility and (2) share a substantial structural feature disclosed as being essential to that utility. In the instant case, the products are polynucleotides that encode separate and distinct polypeptide products, which differ in structure and origin to such an extent that non-coextensive searches are required, and that the polynucleotides are considered to lack a substantial structural feature disclosed as being essential to the disclosed utility. As such, the structurally different polynucleotide products have been restricted each from the other.

Election/Restrictions

3. Restriction to one of the following inventions is required under 35 U.S.C. 121:

Application/Control Number: 09/835,992

Art Unit: 1642

I. Claims 13-17, 31 and 32, drawn to methods for determining gastric cancer or a related condition comprising assaying for an antibody that binds to sterol carrier protein-X/sterol carrier protein-2, classified in class 435, subclass 7.1.

Page 3

- II. Claims 13-17, 31 and 32, drawn to methods for determining gastric cancer or a related condition comprising assaying for an antibody that binds to Protein Kinase B/AKT, classified in class 435, subclass 7.1.
- 4. The inventions are distinct, each from the other because of the following reasons:

Each of groups I and II are drawn to separate and distinct methods because each method uses separate and distinct products. Although there are no provisions under the section for "Relationship of Inventions" in MPEP 806.05 for inventive groups that are directed to different methods, restriction is deemed to be proper because these methods constitute distinct inventions for the following reasons: the antibodies that bind sterol carrier protein-X/sterol carrier protein-2 are separate and distinct products from the antibodies that bind Protein Kinase B/AKT.

Therefore, each of the methods of groups I and II are separate and distinct methods using chemically distinct products unrelated in chemical structure and unrelated in function. Further, it would place an undue burden on the examiner to examine several, independent inventions in one application.

5. In view of the restriction requirement, which is not to be construed as an election of species requirement, Applicant is required to amend any of the claims that are readable on more than one method to be limited to the elected method.

Art Unit: 1642

Application/Control Number: 09/835,992

6. Because these inventions are distinct for the reasons given above and the search required for each of Groups I and II is not coextensive, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even if the requirement is traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the Office should be directed to Anne Holleran, Ph.D. whose telephone number is (703) 308-8892. Examiner Holleran can normally be reached Monday through Friday, 9:30 am to 2:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, Ph.D. can be reached at (703) 308-3995.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist at telephone number (703) 308-0196.

Anne L. Holleran Patent Examiner October 21, 2002

ANTHONY C. CAPUTA
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600